COMMUNIQUÉS West-GlobeNewswire
-
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
08/10/2026 -
Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
08/10/2026 -
Retrieve Medical Announces National Distribution Agreement for Retrieve Passport
08/10/2026 -
SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform
08/10/2026 -
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
08/10/2026 -
IMUNON to Participate in Upcoming Investor Conferences
08/10/2026 -
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
08/10/2026 -
Privia Health to Report Third Quarter 2026 Results on Thursday, November 5
08/10/2026 -
Precision Neuroscience Unveils a New Map of the Human Nervous System
08/10/2026 -
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
08/10/2026 -
Solera Health Launches Cancer Care Network to Connect Members to Digital Cancer Screening, Supportive Care and Treatment Navigation
08/10/2026 -
Fieldstone Bio Selected for Rio Tinto and Founders Factory Mining Tech Accelerator
08/10/2026 -
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
08/10/2026 -
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
08/10/2026 -
World Spine Day 2026: Small Changes Can Make a Big Difference
08/10/2026 -
Sienna Announces Third Quarter 2026 Results Release Date and Conference Call
08/10/2026 -
AnewHealth Names Nationally Recognized Geriatrician and PACE Leader Dr. James Mittelberger Chief Medical Officer
08/10/2026 -
HealthTab™ and HeartEye Open New Referral Pathway into Community Pharmacy
08/10/2026 -
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
08/10/2026
Pages